{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.9"},{"groupId":"OG001","value":"50.6"}]}],"title":"Non-Serious AEs at 2% Threshold: up to 19.3 Month"},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5"},{"groupId":"OG001","value":"62.2"}]}],"title":"Non-Serious AEs at 5% Threshold: up to 49.7 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"A summary of non-serious AEs is located in the Reported Adverse Event Module.","groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","id":"OG000","title":"Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed + cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed Plus Cisplatin Followed by Placebo"}],"paramType":"NUMBER","populationDescription":"Randomized population with 2% cut-off threshold for inclusion for 19.3 months and 5% for 49.7 months.","reportingStatus":"POSTED","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 49.7 months)","title":"Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase","type":"SECONDARY","unitOfMeasure":"percentage of participants"}